Telix Pharmaceuticals Ltd
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TLX in the last 30 days.
See all $TLX insider activity →Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is acquiring ITM Isotope Technologies Munich SE in a $1.65 billion deal, with up to $700 million in additional payments tied to milestones. The acquisition aims to expand Telix's isotope production and therapeutic pipeline.
Telix Pharmaceuticals announced the first U.S. patients have been dosed with Pixclara, its FDA-approved imaging drug for glioma (brain cancer). Pixclara is the only FDA-approved radiopharmaceutical for this indication. The drug is now commercially available in the U.S., supplied by PharmaLogic Holdings Corp.
Sanofi & Regeneron expanded their immunology partnership for up to $8B. Novo Nordisk acquired rights to a drug from Hengrui Pharma for up to $2.6B. Telix Pharmaceuticals to acquire ITM Isotope for up to $2.35B. Merck licensed a cancer drug from SciBrunch for up to $2.13B. Genentech partnered with Earendil Labs for up to $1.5B. GSK acquired a hepatic program from Wave Life Sciences. Lundbeck may acquire Xeris Biopharma.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning TLX (Telix Pharmaceuticals Ltd). Coverage has skewed bullish: 7 bullish, 0 neutral, and 0 bearish.
Recent TLX coverage spans mergers & acquisitions, financial news and regulation.
The deal adds production capacity and therapeutic assets, likely boosting Telix's valuation.
Positive catalyst from product launch.
Acquisition expands Telix’s isotope capabilities.
Buy rating and elevated target could boost the ADR.
Positive catalyst for Telix as the agreement broadens market reach for its solid‑target technology.
AlphAI scores every news story that mentions TLX with an AI model for sentiment and relevance, and aggregates insider trades from Telix Pharmaceuticals Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is acquiring ITM Isotope Technologies Munich SE in a $1.65 billion deal, with up to $700 million in additional payments tied to milestones. The acquisition aims to expand Telix's isotope production and therapeutic pipeline.
1 min readTelix Pharmaceuticals announced the first U.S. patients have been dosed with Pixclara, its FDA-approved imaging drug for glioma (brain cancer). Pixclara is the only FDA-approved radiopharmaceutical for this indication. The drug is now commercially available in the U.S., supplied by PharmaLogic Holdings Corp.
2 min readSanofi & Regeneron expanded their immunology partnership for up to $8B. Novo Nordisk acquired rights to a drug from Hengrui Pharma for up to $2.6B. Telix Pharmaceuticals to acquire ITM Isotope for up to $2.35B. Merck licensed a cancer drug from SciBrunch for up to $2.13B. Genentech partnered with Earendil Labs for up to $1.5B. GSK acquired a hepatic program from Wave Life Sciences. Lundbeck may acquire Xeris Biopharma.
3 min readAnalysts from Wells Fargo and H.C. Wainwright maintained Buy ratings on FedEx (FDX) with a $425 target, Sunbelt Rentals (SUNB) with a $104 target, and Telix Pharmaceuticals (TLX) with a $20 target, citing bullish sentiments.
2 min readIBA and Telix's ARTMS unit agreed to distribute ARTMS's QUANTM® Irradiation System (QIS®) globally. QIS® enables decentralized production of radiometals for theranostics. IBA will offer QIS® to cyclotron customers, aiming to expand theranostics. Both companies aim to advance radiometal-based medicine. IBA is listed on EURONEXT (IBAB.BR, IBAB.BB), Telix on ASX (TLX) and NASDAQ (TLX).
2 min readTelix (TLX) received FDA Fast Track designation for its BiPASS prostate cancer imaging candidate, potentially accelerating development. Positive clinical data or regulatory submissions could serve as larger catalysts, according to the company's press release.
1 min readTelix Pharmaceuticals (TLX) shares fell 10% to $11.28 after announcing a merger deal with ITM Isotope Technologies Munich SE. The stock's 52-week range is $6.28 to $13.11.
1 min readTelix Pharmaceuticals plans to acquire ITM, focusing on expanding Illuccix distribution and investing in its product pipeline. Illuccix, launched in April 2022, is a PSMA imaging agent for prostate cancer and has gained market share due to changes in clinical practice and successful distribution. The company has distribution partners, including Cardinal Health, which operates the largest radiopharmaceutical network in the US.
1 min readNovo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.
2 min readTelix Pharmaceuticals (TLX) will merge with ITM Isotope Technologies Munich SE in a deal valued at up to $2.35B. ITM shareholders will receive $1.25B in Telix shares, with up to $700M in milestone payments. The merger aims to expand Telix's radiopharmaceutical capabilities, including isotope production and manufacturing. ITM generated $273M in 2025 revenue. The deal is subject to shareholder approval, with a vote expected in November 2026.
2 min read
